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Abstract
The biennial Commonwealth Heads of Government Meeting (CHOGM) this year is based around four key themes:
prosperity, fairness, sustainability and security. This is an opportune time to consider the role of pharmacists in
healthcare delivery, and particularly their contribution to achieving the United Nations Sustainable Development
Goals (SDGs). As a member of the Commonwealth Health Professions Alliance (CHPA), the Commonwealth Pharmacists
Association (CPA) has been working to ensure that pharmacy-related aspects of health are represented in the advocacy
papers submitted by Civil Society. Echoing the CHPA’s priorities around SDG 3 (health) and the attainment of sustainable
universal health coverage (UHC), the CPA has been raising the profile of key priorities for our members, including:
addressing the shortage of healthcare workers (with an emphasis on pharmacists); need for access to quality medicines
and medicines information; tackling anti-microbial resistance and substandard/falsified medicines; and championing the
role of digitalisation and partnerships. This editorial discusses how the work of the CPA links with the themes of CHOGM,
the CPA’s input into this meeting and the direction of travel ‘Towards a Common Future’ for health and pharmacy in the
Commonwealth.
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The biennial Commonwealth Heads of Government Mee-
ting (CHOGM) will be hosted in London on 16th–20th
April 2018, with a theme of ‘Towards a Common Future’.
The meeting will provide a platform to discuss current and
common issues affecting the 53 Commonwealth nations,
strengthening efforts to tackle these together [1]. The
themes and priorities of the 2018 CHOGM are prosperity,
fairness, sustainability and security [2]. These themes were
announced last year by the UK’s Prime Minister Teresa
May, and the Prime Minister of Malta Dr. Joseph Muscat,
with the Commonwealth Secretary-General. Papers have
been submitted to the meeting around these themes with
an additional theme invited around “collaboration and
partnership”, emphasizing the collaborative nature of the
Commonwealth and the role of sustainable partnerships for
delivering key priorities. As a member of the Common-
wealth Health Professions Alliance (CHPA), the Common-
wealth Pharmacists Association (CPA) has been working
with other Civil Society organizations to ensure that health
is represented in the submissions. This editorial summa-
rizes how the CPA’s mission to support the better use of
medicines aligns with the CHOGM key themes and health
agenda.
Prosperity
Effective provision of and access to appropriate standards
of healthcare and education underpin prosperous
societies. Although many definitions of prosperity exist, it
is clear that prosperity cannot be achieved without first
having a healthy and educated population [3, 4]. Achieving
Universal Health Coverage (UHC) through effective use of
medicines, and strengthened health systems is essential to
protect the prosperity, health and security of people
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globally. This is something that needs to be continually
highlighted as health and education are often not priori-
tized for investment, with resources being provided to
areas that are more obviously related to prosperity, such
as trade.
Fairness
Reducing health inequalities by ensuring that all people
have access to affordable and appropriate healthcare and
medicines is a definitive part of the fairness agenda, and
linked to better health outcomes [5].Achieving Universal
Health Coverage (UHC) for all members is linked to the
United Nation’s (UN) Sustainable Development Goals
(SDGs), which is a collection of 17 global goals set by
the UN [6]. UHC specifically relates to SDG 3: ‘good
health and wellbeing for all people’, and has been the
focus of many Commonwealth Health Ministers’ mee-
tings. The UK has one of the most well established UHC
systems in the world, but is not the only successful
model. Sri Lanka’s health system provides an example of
how UHC can be achieved with limited resources,
resulting in impressive outcomes [7].For UHC to be
achieved and sustainable, there are multiple aspects that
need to be addressed and invested in.
Sustainability
Access to adequate resources required for effective
health systems is a key part of achieving sustainable pro-
gress towards UHC [8]. This includes appropriately
trained healthcare professionals and resources that
support the delivery of a quality service to the public,
including quality medicines and medicines information.
Alongside access to and sustainable financing of UHC,
developing the health workforce will be one of the areas
of focus for health at the 2018 People’s Forum that runs
alongside the CHOGM.
Developing the health workforce
By 2030, there will be an estimated 18 million shortfall
in healthcare workers, disproportionately concentrated
in low and middle-income countries (LMICs) [9]. Urgent
action is required to transform our health workforce and
fulfil the aspirations of SDG 3 [10]. Access to effective
and safe medicines is a central pillar of any functioning
healthcare system. Medicines remain the most frequent
healthcare intervention worldwide, and national medica-
tion expenditure is second only to human resource costs
in healthcare systems [11]. Expenditure is set to rise fur-
ther as the burden of non-communicable diseases
(NCDs) increases in the globally aging population. As
medicines experts, the pharmaceutical workforce play a
key role in improving health outcomes through optimi-
zing use of medicines [12, 13]. Delivering effective
medicines-related health services relies on investing in
the development of an adaptable, competent and well-
distributed pharmaceutical workforce that can contri-
bute towards achieving UHC, SDGs, and strengthening
health systems [14].
In November 2016, the International Pharmaceutical
Federation (FIP) launched the Pharmacy Workforce
Development Goals (PWDGs) alongside a global vision
for the development of the pharmaceutical workforce
[15]. The PWDGs are a set of measurable, feasible and
tangible goals to implement transformative change for
the global pharmaceutical workforce. The goals are dir-
ectly aligned with major international healthcare policies
and workforce strategies, and the CPA is working in
collaboration with FIP’s education division to support
national pharmacy associations throughout the Com-
monwealth towards national-level implementation of
these goals.
One example of how the CPA is supporting national
pharmacy associations to achieve the PWDGs and ad-
dress the shortfall of appropriately skilled pharmacists
[9] is by developing sustainable models of post-graduate,
pan-Commonwealth training partnerships. The Tropical
Health Education Trust’s (THET) has a successful
Health Partnership Scheme (HPS), which could provide
a model for pharmacist training partnerships. THET and
the CPA share a joint vision to see more pharmacists
included in HPS. WHO’s 3rd global patient safety
challenge: tackling medication-related harm, [16] aims
to reduce medication errors by 50% in 5 years - it is op-
portune timing to increase the pharmaceutical workforce
to help achieve this goal.
Ensuring access to reliable and independent resources of
medicines information
Having access to reliable and independent medicines
information is key for the provision of evidence-based
care and achieving positive health outcomes, [17] yet
many healthcare providers do not have access to quality
medicines information. The CPA’s PharmAid scheme
(the redistribution of recent editions of medicines infor-
mation resources to LMICs in the Commonwealth) has
sent over 200,000 books to 28 Commonwealth countries
since 2005. In a recent survey, 80% of PharmAid
recipients stated that the resources provided through
PharmAid were very useful, or their practice would not
be the same without them.
Security
Response to pandemics and infectious disease
The recent Ebola and Zika outbreaks are clear examples
of how pandemics can present a threat to global health
security. The WHO has declared that antimicrobial re-
sistance (AMR) is also global health security threat, [18]
and it is estimated that people are more likely to die
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from drug-resistant infections than cancer by 2050 if
AMR is not addressed immediately. This issue is magni-
fied in LMICs, where the incidence of AMR is much
higher and significantly under-reported. In September
2016, 193 countries of the United Nations agreed to a
landmark declaration to ‘rid the world of superbugs’,
which all Commonwealth countries signed. Of these,
44% have a current action plan, 27% have an action plan
under development, and 29% do not yet have an estab-
lished plan [19].
The CPA has been raising awareness of AMR through
their global campaigns, webinars, and resources to help
National Pharmacy Associations and their members de-
velop their own campaigns, adhere to best practices to
reduce inappropriate use of antimicrobials [20]. The
CPA have involved health ministers and their represen-
tatives through the Commonwealth Advisory Committee
on Health (CACH) in Colombo 2016, and hosted pre-
sentations, workshops and discussions at international
conferences in Australia and Sri Lanka, to ensure AMR
is high priority.
A recent partnership between the CPA and health
behaviour change specialists Spoonful of Sugar has been
pivotal for understanding the behavioural drivers of
AMR across the Commonwealth. Understanding and
tackling behaviour is important in the battle against
AMR. In LMICs, pharmacists may have motivations and
underlying beliefs associated with running a business
and maintaining customer loyalty [21, 22], particularly
when patients seek antimicrobials [23, 24], that are dis-
cordant with antimicrobial stewardship (AMS) and drive
inappropriate antimicrobial use.
Substandard and falsified medicines
It is estimated that up to 50% of medicines in some parts of
the world are substandard or falsified, with an estimated
700,000 people dying each year due to fake malaria and tu-
berculosis medication [25]. Regulation, monitoring and
education are amongst the aspects that need to be
addressed to tackle this. As partners of the Fight the Fakes
– a campaign that aims to raise awareness on the dangers
of fake medicines [26], the CPA has been advocating to
highlight this issue in the Commonwealth through
campaigns and advocacy efforts.
The role of digitilisation
There is a need to support all member nations to ensure
that there is a Commonwealth-wide surveillance
capacity and networks to help detect, isolate, monitor
and co-ordinate responses to potential disease outbreaks.
It is hoped that the Commonwealth Digital Health Ini-
tiative (CWDIH), which was recently established by the
Commonwealth Medical Association (CMA) and is due
for launch during CHOGM 2018, will take on
monitoring as one of its key roles. In addition to provid-
ing digital response around pandemics and AMR, the
CWDIH could also improve reporting of substandard
and falsified medicines. The wider implications of digi-
talisation on the delivery of medicines-related healthcare
services, and the training of healthcare professionals,
also need consideration.
Partnerships
Partnership relates to SDG 17. The Commonwealth
provides a network that could potentially support all
countries to achieve UHC through collaborative working.
The 2016 Colombo Declaration highlighted the commit-
ment of organizations to work together to deliver an action
plan to improve the health and wellbeing of the Common-
wealth. Similarly, delivery of agreed actions from CHOGM
could be supported through pan-Commonwealth partner-
ships. Combining expertise to create a multi-disciplinary,
pan-Commonwealth, public-private sector approach will be
crucial to tackle the issues facing health and wellbeing
today and in the future.
Summary
The upcoming CHOGM is a key opportunity to reener-
gize the Commonwealth and empower the people towards
a shared goal of building a common future to improve
health. In terms of the joint aspirations of achieving UHC,
SDGs and strengthening health systems, investment in the
pharmacy workforce using a pan-Commonwealth partner-
ship approach in collaboration with pharmacist profes-
sional bodies such as the CPA is a positive and welcome
step in the right direction.
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